U
BCLI

UBS’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

UBS’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$3K Buy
+44
New +$2.71K ﹤0.01% 9766

Other funds holding BCLI

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

UBS's BCLI Position: Q3 2014 in Review

UBS opened a new position in BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2014: 44 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #9766 among its holdings.

7 funds tracked by Wall St. Rank hold BCLI as of Q3 2014.

  • UBS held 44 shares of BRAINSTORM CELL THERAPUTC worth $3K as of Q3 2014.
  • BRAINSTORM CELL THERAPUTC was a new UBS position in Q3 2014.
  • BRAINSTORM CELL THERAPUTC made up ﹤0.01% of UBS's portfolio in Q3 2014, its #9766 holding.
  • 7 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.